Literature DB >> 28078787

Targeting nasopharyngeal carcinoma by artesunate through inhibiting Akt/mTOR and inducing oxidative stress.

Qin Li1, Wei Ni1, Zhifeng Deng1, Minghe Liu1, Lazhi She1, Qiong Xie1.   

Abstract

Drug repurposing has become an alternative therapeutic strategy for cancer treatment given the known pharmacokinetics and toxicity. The inhibitory effects of artesunate have been reported in various cancers. In this work, we investigated the effects of artesunate in nasopharyngeal carcinoma (NPC). We demonstrate that artesunate significantly inhibits proliferation via arresting NPC cells at G2/M phase. It also induces apoptosis through caspase-dependent and mitochondria-independent pathways in multiple NPC cell lines. The combination of artesunate and cisplatin is synergistic in targeting NPC cells in in vitro cellular culture system and in vivo xenograft tumor models. Artesunate inhibits phosphorylation of essential molecules involved in Akt/mTOR pathway in NPC cells, such as Akt, mTOR, and 4EBP1, and its inhibitory effects are partially abolished by overexpression of constitutively active Akt. In addition, artesunate also induces mitochondrial dysfunction and oxidative stress via inhibiting mitochondrial respiration, increasing levels of mitochondrial superoxide and cellular reactive oxygen species (ROS), leading to decreased ATP levels. Two ROS scavengers partially abolish the inhibitory effects of artesunate in NPC cells. These data suggest that both inhibition of Akt/mTOR pathway and induction of ROS are required for the action of artesunate in NPC cells. Our work demonstrates that artesunate is a potential candidate for NPC treatment. Our work also highlights the critical roles of Akt/mTOR pathway and mitochondrial function in NPC cells.
© 2017 Société Française de Pharmacologie et de Thérapeutique.

Entities:  

Keywords:  Akt/mTOR; artesunate; mitochondria; nasopharyngeal carcinoma; oxidative damage

Mesh:

Substances:

Year:  2017        PMID: 28078787     DOI: 10.1111/fcp.12266

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  11 in total

1.  Antimalarial drug artesunate is effective against chemoresistant anaplastic thyroid carcinoma via targeting mitochondrial metabolism.

Authors:  Ling Ma; Honghua Fei
Journal:  J Bioenerg Biomembr       Date:  2020-02-08       Impact factor: 2.945

2.  Artesunate targets oral tongue squamous cell carcinoma via mitochondrial dysfunction-dependent oxidative damage and Akt/AMPK/mTOR inhibition.

Authors:  Qingfeng Xiao; Lei Yang; Hao Hu; Yue Ke
Journal:  J Bioenerg Biomembr       Date:  2020-01-21       Impact factor: 2.945

Review 3.  Anti-malarial drug, artemisinin and its derivatives for the treatment of respiratory diseases.

Authors:  Dorothy H J Cheong; Daniel W S Tan; Fred W S Wong; Thai Tran
Journal:  Pharmacol Res       Date:  2020-05-13       Impact factor: 7.658

4.  Artesunate-induced mitophagy alters cellular redox status.

Authors:  Jianbin Zhang; Xin Sun; Liming Wang; Yin Kwan Wong; Yew Mun Lee; Chao Zhou; Guoqing Wu; Tongwei Zhao; Liu Yang; Liqin Lu; Jianing Zhong; Dongsheng Huang; Jigang Wang
Journal:  Redox Biol       Date:  2018-08-04       Impact factor: 11.799

5.  Preclinical Evaluation of Artesunate as an Antineoplastic Agent in Ovarian Cancer Treatment.

Authors:  Anthony McDowell; Kristen S Hill; J Robert McCorkle; Justin Gorski; Yilin Zhang; Ameen A Salahudeen; Fred Ueland; Jill M Kolesar
Journal:  Diagnostics (Basel)       Date:  2021-02-26

6.  Artesunate Impairs Growth in Cisplatin-Resistant Bladder Cancer Cells by Cell Cycle Arrest, Apoptosis and Autophagy Induction.

Authors:  Fuguang Zhao; Olesya Vakhrusheva; Sascha D Markowitsch; Kimberly S Slade; Igor Tsaur; Jindrich Cinatl; Martin Michaelis; Thomas Efferth; Axel Haferkamp; Eva Juengel
Journal:  Cells       Date:  2020-12-09       Impact factor: 6.600

7.  KEAP1 Is Required for Artesunate Anticancer Activity in Non-Small-Cell Lung Cancer.

Authors:  Kristen S Hill; Anthony McDowell; J Robert McCorkle; Erin Schuler; Sally R Ellingson; Rina Plattner; Jill M Kolesar
Journal:  Cancers (Basel)       Date:  2021-04-14       Impact factor: 6.639

8.  Artesunate attenuates proliferation of epithelial cells by downregulating the NF-κB and AKT signaling pathways in benign mammary gland hyperplasia rats.

Authors:  Wei Li; Lina Zhao; Yiliang Li; Zhen Zhai
Journal:  Ann Transl Med       Date:  2021-05

9.  DHA exhibits synergistic therapeutic efficacy with cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via modulation of iron metabolism.

Authors:  Jing Du; Xu Wang; Yanchun Li; Xueying Ren; Yi Zhou; Wanye Hu; Chaoting Zhou; Qiangan Jing; Chen Yang; Luyang Wang; Huanjuan Li; Lijuan Fang; Yonglie Zhou; Xiangmin Tong; Ying Wang
Journal:  Cell Death Dis       Date:  2021-07-15       Impact factor: 8.469

Review 10.  The Akt pathway in oncology therapy and beyond (Review).

Authors:  George Mihai Nitulescu; Maryna Van De Venter; Georgiana Nitulescu; Anca Ungurianu; Petras Juzenas; Qian Peng; Octavian Tudorel Olaru; Daniela Grădinaru; Aristides Tsatsakis; Dimitris Tsoukalas; Demetrios A Spandidos; Denisa Margina
Journal:  Int J Oncol       Date:  2018-10-16       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.